A Trimethoprim Conjugate of Thiomaltose Has Enhanced Antibacterial Efficacy In Vivo.

Trimethoprim is one of the most widely used antibiotics in the world. However, its efficacy is frequently limited by its poor water solubility and dose limiting toxicity. Prodrug strategies based on conjugation of oligosaccharides to trimethoprim have great potential for increasing the solubility of trimethoprim and lowering its toxicity, but they have been challenging to develop due to the sensitivity of trimethoprim to chemical modifications, and the rapid degradation of oligosaccharides in serum. In this report, we present a trimethoprim conjugate of maltodextrin termed TM-TMP, which increased the water solubility of trimethoprim by over 100 times, was stable to serum enzymes, and was active against urinary tract infections in mice. TM-TMP is composed of thiomaltose conjugated to trimethoprim, via a self-immolative disulfide linkage, and releases 4'-OH-trimethoprim (TMP-OH) after disulfide cleavage, which is a known metabolic product of trimethoprim and is as potent as trimethoprim. TM-TMP also contains a new maltodextrin targeting ligand composed of thiomaltose, which is stable to hydrolysis by serum amylases and therefore has the metabolic stability needed for in vivo use. TM-TMP has the potential to significantly improve the treatment of a wide number of infections given its high water solubility and the widespread use of trimethoprim.

[1]  Hua-lin Fu,et al.  Solubility of Trimethoprim in Selected Pure Solvents and (Water + Ethanol/2-Propanol) Mixed-Solvent Systems , 2016 .

[2]  L. Hanff,et al.  Development and Validation of an HPLC–UV Assay to Quantify Plasma Levels of Sulfametrol: A Preferential Antibiotic in Children , 2015, Therapeutic drug monitoring.

[3]  S. Hultgren,et al.  Urinary tract infections: epidemiology, mechanisms of infection and treatment options , 2015, Nature Reviews Microbiology.

[4]  D. Weiss,et al.  PET imaging of bacterial infections with fluorine-18-labeled maltohexaose. , 2014, Angewandte Chemie.

[5]  S. Gambhir,et al.  Investigation of 6-[18F]-Fluoromaltose as a Novel PET Tracer for Imaging Bacterial Infection , 2014, PloS one.

[6]  G. H. Thomas,et al.  Probing Bacterial Uptake of Glycosylated Ciprofloxacin Conjugates , 2014, Chembiochem : a European journal of chemical biology.

[7]  Johnny X. Huang,et al.  Structure aided design of chimeric antibiotics. , 2012, Bioorganic & medicinal chemistry letters.

[8]  L. Barreto,et al.  Physicochemical study and characterization of the trimethoprim/2-hydroxypropyl-γ-cyclodextrin inclusion complex. , 2012, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[9]  G. R. Andrade,et al.  Structural and theoretical-experimental physicochemical study of trimethoprim/randomly methylated-β-cyclodextrin binary system. , 2011, Carbohydrate research.

[10]  D. Juurlink,et al.  Considerations when prescribing trimethoprim–sulfamethoxazole , 2011, Canadian Medical Association Journal.

[11]  M. King,et al.  Antibacterial Activity of β-Cyclodextrin and 2-Hydroxypropyl- β β β β-Cyclodextrin Trimethoprim Complexes , 2011 .

[12]  Dongin Kim,et al.  Maltodextrin-based imaging probes detect bacteria in vivo with high sensitivity and specificity. , 2011, Nature materials.

[13]  D. Genovese,et al.  Studies on trimethoprim:hydroxypropyl-β-cyclodextrin: aggregate and complex formation. , 2010, Carbohydrate research.

[14]  W. Goebel,et al.  Maltose and Maltodextrin Utilization by Listeria monocytogenes Depend on an Inducible ABC Transporter which Is Repressed by Glucose , 2010, PloS one.

[15]  S. Hultgren,et al.  A murine model of urinary tract infection , 2009, Nature Protocols.

[16]  Nadine Shehab,et al.  Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates , 2009, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[17]  N. Vermeulen,et al.  Trimethoprim: novel reactive intermediates and bioactivation pathways by cytochrome p450s. , 2008, Chemical research in toxicology.

[18]  W. Boos,et al.  The Maltodextrin System of Escherichia coli: Metabolism and Transport , 2005, Journal of bacteriology.

[19]  Yahui Zhang,et al.  Inclusion complex of trimethoprim with β-cyclodextrin , 2005 .

[20]  S. Queener,et al.  Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium. , 2004, Bioorganic & medicinal chemistry letters.

[21]  P. Klebba.  Mechanism of maltodextrin transport through LamB. , 2002, Research in microbiology.

[22]  J. Logie,et al.  Antibiotic failure in the treatment of urinary tract infections in young women. , 2001, The Journal of antimicrobial chemotherapy.

[23]  K. Hryniewicz,et al.  Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. , 2001, The Journal of antimicrobial chemotherapy.

[24]  A. Schaeffer,et al.  Urinary tract infection in adults: research priorities and strategies. , 2001, International journal of antimicrobial agents.

[25]  B. Vu,et al.  Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials. , 1999, Journal of medicinal chemistry.

[26]  Kurt Stockinger,et al.  Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection , 1997, European Journal of Clinical Nutrition.

[27]  W. Hughes.  Pneumocystis carinii pneumonia: new approaches to diagnosis, treatment and prevention. , 1991, The Pediatric infectious disease journal.

[28]  E. Yamato,et al.  Metabolism of intravenously administered maltose in renal tubules in humans. , 1990, The American journal of clinical nutrition.

[29]  S. Freundlieb,et al.  Facilitated diffusion of p-nitrophenyl-alpha-D-maltohexaoside through the outer membrane of Escherichia coli. Characterization of LamB as a specific and saturable channel for maltooligosaccharides. , 1988, The Journal of biological chemistry.

[30]  J. Remington,et al.  Intravenous trimethoprim-sulfamethoxazole therapy for Pneumocystis carinii pneumonia. , 1981, The American journal of medicine.

[31]  R. Vejlsgaard,et al.  Treatment of urinary tract infections in general practice with sulfamethizole, trimethoprim or co-trimazine (sulphadiazine-trimethoprim). , 1980, The Journal of antimicrobial chemotherapy.

[32]  K. Tsutsumi,et al.  Distribution of maltose intravenously administered to rabbits and its metabolism in the kidney. , 1974, The Tohoku journal of experimental medicine.

[33]  E. Weser,et al.  The metabolism of circulating maltose in man. , 1971, The Journal of clinical investigation.

[34]  S. Moore,et al.  THE CONCENTRATIONS OF CYSTEINE AND CYSTINE IN HUMAN BLOOD PLASMA. , 1960, The Journal of clinical investigation.

[35]  F. Veiga,et al.  Preparation and characterization of Trimethoprim inclusion complex with Methyl-β-Cyclodextrin and determination of its antimicrobial activity , 2015 .

[36]  H. Nikaido,et al.  Specificity of diffusion channels produced by lambda phage receptor protein of Escherichia coli. , 1980, Proceedings of the National Academy of Sciences of the United States of America.